Turkey: Is Serving An Eight Year Ban A REAL Settlement For An Athlete? (Case Study)

The Court of Arbitration for Sport (CAS) has issued a Consent Arbitral Award in the arbitration procedure between the International Association of Athletics Federations (IAAF), the Turkish Athletic Federation (TAF) and Turkish middle-distance runner, Asli Cakir-Alptekin (the Athlete).

The Consent Arbitral Award ratifies a settlement agreement signed by the parties. The settlement relates to abnormal values found in the Athlete's blood samples, collected between July 2010 and October 2012. The incident is Ms Cakir-Alptekin's second violation of anti-doping rules, with the first incident occurring in 2004. As a result of the latest incident, she will be ineligible to compete for eight years. Furthermore, all competitive results obtained by the Athlete from 29 July 2010 onwards have been disqualified, along with forfeiture of all related titles, awards, medals, points and appearance money. These include a gold medal won at the 2012 London Olympic Games, as well as a gold medal won at the European Championships in the same year.

This article analyses the case's factual background, terms of the settlement, and the CAS decision, as well as provides comments on the likely rationale behind the settlement. The analysis is made exclusively based on disclosed documents and in no way intends to harm or defame the parties involved in the proceedings.

Commentary: As the name suggests, a settlement by its nature must require compromise from both sides. Such compromise ensures the parties are motivated to reach an amicable agreement. Thus, the parties avoid lengthy and costly proceedings, as well as a verdict which could either be worse than the outcomes available through settlement, or involve an uncertain outcome due to the circumstances.

However, given the terms of this settlement, questions arise about what Ms Cakir-Alptekin achieved through agreeing to a settlement, compared to the likely award which the CAS would have made if no settlement had been reached.

The Athlete in these circumstances will be ineligible to compete until 9 January 2021. By the time the ban is lifted, she will be too old to realistically compete in any international event. In effect, this so-called settlement is highly likely to mean Ms Cakir-Alptekin will not be able to run another major event for the rest of her life.

Given the settlement's unfavourable consequences for the Athlete, questions arise about whether rather than agreeing with this unfavourable settlement, it was worth opposing the IAAF's appeal before the CAS, relying on the TAF decision, its reasoning, or the evidence used. Obviously, fighting for a career which hangs in the balance will takes priority over any other gains accomplished through a settlement with these terms. However, in these circumstances, it seems that mystery will continue to surround why Ms Cakir-Alptekin and the TAF took such a position.

Facts and Dispute Resolution Procedure

In January 2013, the IAAF charged the Athlete with an anti-doping rule violation on the basis of her Athlete Biological Passport. The athlete's case was heard by the TAF Disciplinary Board, which gave a ruling in December 2013 that no penalty should be imposed.

The TAF Disciplinary Board's decision held that the Athlete Biological Passport's evidence (as submitted by the IAAF) was insufficient to support an anti-doping rule violation and the Athlete should be exonerated accordingly.

The IAAF disagreed with the TAF Disciplinary Board's decision to exonerate the Athlete, referring the case to the CAS. Before a hearing could be held as part of the CAS procedure, the parties entered negotiations and reached a settlement agreement, which has now been ratified by the CAS Consent Arbitral Award.

Before accepting the settlement, the athlete argued before the CAS that "she has not manipulated her blood as asserted by the IAAF (i.e. in a manner which is prohibited), and therefore has not committed any anti-doping rule violation as alleged." The Athlete claimed that "any anomalies in her blood profile are explicable by various factors (and combinations of them), including (i) living and training at altitude, (ii) use of altitude-simulating techniques, and/or (iii) medical issues. She further alleged that the IAAF has not proved the allegations to the requisite standard, particularly in light of the evidence she submitted."

The TAF did not respond to the IAFF's allegations at any stage during the CAS proceedings.

As a last attempt on 26 May 2015, prior to reaching the settlement, the Athlete provided a witness statement to the CAS, made by Dr. Ahmet Karadac. The statement has not been disclosed, but presumably supports the Athlete's arguments.

Settlement Details

On 29 May 2015, the parties informed the CAS Court Office that they had reached a settlement and therefore the hearing would no longer be needed. The parties asked the Panel to ratify their Settlement Agreement.

In the settlement agreement, the Athlete acknowledged the abnormality of certain values in her Athlete Biological Passport relating to blood samples collected between 29 July 2010 and 17 October 2012. The Athlete also acknowledged that she is unable to substantiate the explanations she has offered for those values. Finally, the Athlete conceded that she is unable to rebut the IAAF's assertion that the values are the result of some form of blood manipulation, contrary to IAAF Rule 32.2(b).

Commentary: If the case had proceeded, the CAS could not have handed down any worse outcome for the Athlete. Such a wide admission and concession by the Athlete under the auspices of a settlement does not seem to sit comfortably with the notion of a settlement, unless other motives exist for the Athlete.

The IAAF acknowledged that after the IAAF's revision of its Anti-Doping Rules from 1 January 2015 onwards to reflect the provisions of the 2015 World Anti-Doping Code, Ms Cakir-Alptekin is entitled to argue that the maximum period of ineligibility for a second anti-doping rule violation of this type is eight years (IAAF Rule 40.8(a)(iii)).

Commentary: Arguably the CAS would take this view anyway [only] if the evidence proves without any doubt that those values are the result of some form of blood manipulation contrary to IAAF Rule 32.2(b). This does not therefore seem to be a real gain by the Athlete. By agreeing with a settlement and not raising her arguments concerning the lack of causation between the blood test and competition results, the Athlete agreed (effectively) to end her career since she will be too old to compete in major events by the time the time her ineligibility expires.   

The TAF made no comment on the IAAF's positions or the Athlete. However, the TAF declared that it reserves its right to claim reimbursement of all the prize money paid by the General Directorate of Sports of Turkey to Ms Cakir-Alptekin regarding certain medals identified in the settlement.

The settlement was made relatively quickly and the athlete accepted:

  • Some form of blood manipulation occurred between 29 July 2010 and 17 October 2012. This accusation was upheld by default.
  • She is ineligible to compete until 10 January 2021.
  • Disqualification of all competitive results obtained from 29 July 2010 onwards, along with forfeiture of all related titles, awards, medals, points, and prize and appearance money are forfeited.
  • She will, equally with the TAF, bear the CAS arbitration costs (to be determined and notified by the CAS Court Office in due course).

The CAS issued a Consent Arbitral Award which ratifies the parties' settlement agreement, except for a minor part in relation to the reimbursement of the CAS Court Office Fees.

Commentary: Arguably, if all of the Athlete's and the TAF's arguments were refused, this outcome could have been the CAS Court's decision anyway. Therefore, questions arise about why the Athlete and the TAF did not fight for the case.

On the face of things, it seems the only gain the athlete achieved by agreeing to the settlement is that the parties agreed to bear their own legal costs, as well as other costs incurred in connection with the arbitration. An exception being that the Athlete and the TAF are jointly and severally liable to pay the IAAF an undisclosed agreed sum as a contribution towards its costs (due within 14 days of the settlement agreement).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.